Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Wyden 2017 Chronic-Care Bill Would Reward Telemedicine, Home-Use Devices

Executive Summary

Sen. Ron Wyden, D-Ore., ranking member of the Senate Finance Committee, plans to reintroduce chronic-care legislation in 2017 that would lead to more Medicare reimbursement of home-use devices and telemedicine options for elderly patients with multiple conditions.

You may also be interested in...

US House Bills Address Telemedicine, Prostate Cancer Tests, Diabetes Supplies

A slate of bills recently approved by the US House Energy and Commerce Health Subcommittee seek to give Medicare stroke beneficiaries better access to telemedicine, provide coverage of DNA-based prostate cancer tests, and make changes to CMS's competitive bidding program for durable medical equipment to ensure diabetic beneficiaries receive diabetes test strips.

Telehealth Reforms Praised At Senate Hearing

Insurers and a neurologist testifying at a May 16 Senate Finance Committee hearing on the CHRONIC Care Act praised the bill's telehealth provisions. Committee Chairman Orrin Hatch, R-Utah, says he plans to mark up the bill, which has been under development for two years, this week.

Senate HELP Advances Device Review Reform Bills

The Senate Health, Education, Labor and Pensions Committee approved a slate of bills Feb. 9, including the Device Accountability Act, which enhances focus on the "least burdensome" concept for device review, and legislation intended to improve oversight of modified devices and device reprocessing.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts